



1636
\$

PATENT
600-1-087CIP2I

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Jeffrey Friedman, *et al.*

EXAMINER: YUCEL, I.

CONTINUED PROSECUTION APPLICATION OF
SERIAL NO.: 08/485,943

ART UNIT: 1636

FILED: June 7, 1995

FOR: MODULATORS OF BODY WEIGHT, CORRESPONDING
NUCLEIC ACIDS AND PROTEINS, AND DIAGNOSTIC
AND THERAPEUTIC USES THEREOF

RECEIVED

MAR 08 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231 on February 28, 2001.

Christine E. Dietzel, Reg. 37,309
(Name of Registered Representative)

Joan A. Santner 2/28/01
(Signature and Date)

AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231

Dear Sir:

The present paper is filed in response to an official action received August 29, 2000. This paper is timely filed by virtue of the attached three month extension of time attached herewith. Applicants thank the Examiner for the interview on February 14, 2001.

REMARKS

Summary of the rejection:

Claims 124, 132-137, 139-143, 145-153, 155-160 and 163-173 stand rejected under 35 U.S.C. §112, first paragraph. It is the Examiner's contention that the specification does not provide a sufficient disclosure to enable one of skill in the art to employ gene therapy protocols for the intervention of obesity commensurate with the scope of the claimed invention. In essence, the Examiner appears to maintain that in order for the application to be properly enabled, it should provide specific and particular details of protocols to be used. Applicants traverse the rejection and provide the following response.